Objective DNA malignancy grading as adjunct to the histological Gleason score

Böcking, Alfred; Biesterfeld, Stefan; Dietz, Josef; Haroske, G.; Kriegsmann, Jörg; Motherby, H; Falk, Stan

doi:10.1007/s00292-015-0074-3

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As these measurements so far were too time consuming, they were hardly accepted in routine diagnostics. Yet, meanwhile cancer cell-nuclei can automatically be identified by digital classifiers, trained by cytopathologists [12] and differentiated from nuclear doublets, artifacts, lymphocytes, granulocytes and fibroblasts (as potential reference cells). This new technology is called DNA-karyometry [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction of Non-Progression in Prostate Cancer Patients under Active Surveillance by DNA-Karyometry

Böcking¹,

Friedrich²,

Börgermann³

et al. 2017

SM J Uro

View full text Add to dashboard Cite

The option of Active Surveillance for patients with localized prostate cancer depends on a low Gleason-Score (GS) of 6. Nevertheless about 30%have to face clinical progression within five years.Our hypothesis is that automated measurements of DNA-content of prostate cancer cells yield a DNA-grade of malignancy [1][2][3][4] that is able to predict non-progression of prostate cancers at much higher accuracy than the subjective GS.Nuclear DNA-measurements were performed from cancer tissue in residual biopsy-material of 80 patients from the HAROW-study. Local-and a reference pathologists GSs were available. Follow-up of mean 4,1 years included repeated PSA-values, number and GSs of positive biopsies, clinical stage, and in19cases results from prostatectomies.Reproducibility of GSs was 55% without and 45% with differentiation between 6 and 7a. Progression occurred in 37.5% if upgrade of any inclusion criterion was used as evidence and in 18,8% if only PSA-DT <36 months or upstaging to pT3. Prevalence of DNA-grade 1 was 40%.Sensitivity, specificity and negative predictive value of local pathologists GS, reference pathologists GS and DNA-karyometry were: 0%, 95.0% and 74.0%, 20.0%, 86.7% and 76.5%, 85.0%, 51.0% and 90.6%, if upgrade of any criterion of inclusion was used as evidence of progression and 5.9%, 96.8% and 79.2%, 23.5%, 87.3% and 80.9%, 100%, 50.8% and 100% if only PSA-DT < 36 months and/or upstaging to pT3 were used.Thus, objective automated DNA-karyometry can much more reliably exclude progression of prostate cancers under Active Surveillance within four years as compared with subjective Gleason-scoring.

show abstract

Section: Introductionmentioning

confidence: 99%

“…This new technology is called DNA-karyometry [14]. German pathologists have recently agreed on the Frankfurt Consensus in which most technical details of prognostic DNAkaryometry for cancers of the prostate are stated, including details of diagnostic interpretation of DNA-histograms [12].…”

Section: Introductionmentioning

confidence: 99%

Prediction of Non-Progression in Prostate Cancer Patients under Active Surveillance by DNA-Karyometry

Böcking¹,

Friedrich²,

Börgermann³

et al. 2017

SM J Uro

View full text Add to dashboard Cite

show abstract

Prostate cancer

Helpap

Bubendorf

2016

Pathologe

View full text Add to dashboard Cite

Using tritium-labeled thymidine histoautoradiography, the AgNOR staining technique and Ki67-MIB-1 immunohistochemistry to study cell kinetics, prostate cancer can be subdivided into slowly, moderately and rapidly proliferating tumors. These are important supplementary methods and prerequisites for a grading as low, intermediate and high-grade in addition to classical histology and cytology. Cytometry of DNA can confirm the cell kinetics of prostate cancer by detection of a predominance of diploid or aneuploid cell nuclei but should only be evaluated together with histological investigations. All histology-based analyses of cell kinetics encompass the classical highly and poorly differentiated glandular and cribriform patterns as well as solid undifferentiated structures and the various subcategories. The malignancy grading of prostate cancer can result from the summation of histological grading and cell kinetic analyses, as long as the named investigations are included. The future perspectives of individualized therapy options, including active surveillance in early low-grade and also for high-grade prostate cancer and new antihormonal treatment in advanced disease, may increasingly rely on tissue biomarkers and advanced technologies for whole genome analysis including next generation sequencing.

show abstract

Objective DNA malignancy grading as adjunct to the histological Gleason score

Cited by 2 publications

References 8 publications

Prediction of Non-Progression in Prostate Cancer Patients under Active Surveillance by DNA-Karyometry

Prediction of Non-Progression in Prostate Cancer Patients under Active Surveillance by DNA-Karyometry

Prostate cancer

Contact Info

Product

Resources

About